Stem Cell Transplantation for Patients With Cancers of the Blood

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
CML (Chronic Myelogenous Leukemia)CLL (Chronic Lymphocytic Leukemia)AML (Acute Myelogenous Leukemia)Acute Lymphocytic LeukemiaMDS (Myelodysplastic Syndrome)
Interventions
COMBINATION_PRODUCT

Miltenyi system

Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00467961 - Stem Cell Transplantation for Patients With Cancers of the Blood | Biotech Hunter | Biotech Hunter